After Remdesivir's Emergency Use Authorization, US Gov't Must Now Decide How To Distribute Limited Supply
Gilead's antiviral remdesivir will go to hospitalized severe COVID-19 patients per FDA's EUA. Some cities could receive the medicine with days, but it is not clear how the government will dole out the limited supplies. FDA said it had access to non-public data from a key NIH trial during its EUA review.
You may also be interested in...
Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.
As it prepares to report second quarter earnings that may show coronavirus-related impacts, the company’s antiviral for COVID-19 may boost 2020 revenue and offset need for new products.
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.